GlassScriptPhysician profile
Heather D Nielsen
NPI 1366861981
$9,313.92
in general payments reported to CMS, 2019-2025
51 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $525 · 2021: $1,417 · 2022: $1,015 · 2023: $1,801 · 2024: $1,571 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,105 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,104.68 |
| Education | $149.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,238.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $841.56 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.91 | 2019-2025 | Jardiance |
| Abbvie INC. | $760.04 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $746.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $676.39 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Lilly USA, LLC | $637.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $460.09 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $239.39 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Merck Sharp & Dohme LLC | $202.62 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Biohaven Pharmaceuticals, INC. | $179.18 | 2021 | |
| Astellas Pharma US INC | $168.36 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $165.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $160.79 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $152.19 | 2019-2024 | Spravato |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Nielsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.